Phase II study with docetaxel (D), cisplatin (C), and continuous capecitabine (CAP) combination (TCX) in advanced gastric cancer: Preliminary data.

e14611 Background: Activity in first line in advanced gastric carcinoma with D, C and CAP has been describe. But there is no much information about continuous treatment with capecitabine in this setting. We performed this study in order to obtain data in this patients. Methods: Patients (pts) were enrolled if they had the main subsequent criteria: histologically confirmed diagnosis of advanced gastric cancer (AGC) (local advanced or metastatic disease); normal renal and hepatic function; no myocardial infarction or angina pectoris; no uncontrolled severe diseases or active infections. Treatment schedule: D at fixed dose of 75 mg/m2 on day 1, C at fixed dose of 60 mg/m2 on day 1, CAP at fixed dose of 1,300 mg/m2 in two daily administration from day 1 to day 21, every 3 weeks. Colony stimulating factors were used as a primary profilaxis. Dose-limiting toxicity (DLT): Grade (G) 3 non-haematological or G4 haematological. Study design: Open phase II trial. Primary endpoint was response rate (RR). Secondary end...